BELLUS Health Inc. (BLU)
- Zacks
BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
- Business Wire
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
LAVAL, Quebec, September 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prur
- The Motley Fool
4 Canadian Stocks That Could Soar 68% or More According to Bay Street
If you're looking for Canadian growth stocks to buy, these four Canadian companies are some of the best opportunities on the TSX today. The post 4 Canadian Stocks That Could Soar 68% or More According to Bay Street appeared first on The Motley Fool Canada.
